ArticleWorld journal of gastroenterology2017
Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Article in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 6 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Pooled it
- Pooled it
- Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review.Health technology assessment (Winchester, England) · 2021Pooled it
- Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review.World journal of gastroenterology · 2021Pooled it
- A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review.The American journal of gastroenterology · 2019Pooled it
- Approach to gastroenterological diseases in primary care.Acta bio-medica : Atenei Parmensis · 2018Pooled it
- Effect of Fish-Derived Lipids on Inflammation Status and Health-Related Quality of Life in Women with Endometriosis.Nutrients · 2026Trial
- Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program.Inflammatory bowel diseases · 2025Trial
- LIAISONUnited European gastroenterology journal · 2022Trial
- Integrating Intestinal Ultrasound in the Personalized Management of IBD.Journal of personalized medicine · 2026Review
- Physiological Data Collected From Wearable Devices Identify and Predict Inflammatory Bowel Disease Flares.Gastroenterology · 2025Observational
- Observational
- Adherence to the Mediterranean Diet Is Associated with Decreased Fecal Calprotectin Levels in Children with Crohn's Disease in Clinical Remission under Biological Therapy.Digestive diseases (Basel, Switzerland) · 2024Article
- Monitoring of Inflammatory Bowel Disease in Pregnancy: A Review of the Different Modalities.Journal of clinical medicine · 2023Review
- Beneficial Effects of Plant Oils Supplementation on Multiple Sclerosis: A Comprehensive Review of Clinical and Experimental Studies.Nutrients · 2023Review
- Peripheral blood T-lymphocyte subsets are potential biomarkers of disease severity and clinical outcomes in patients with ulcerative colitis: a retrospective study.BMC gastroenterology · 2023Article
- Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2023Review
- Programming Factors of Neonatal Intestinal Dysbiosis as a Cause of Disease.International journal of molecular sciences · 2023Review
- The use of calgranulin-C (S100A12) and fecal zonulin as possible non-invasive markers in children with inflammatory bowel disease: a clinical study.European journal of pediatrics · 2023Article
- Diagnostic Accuracy of Fecal Calprotectin for Predicting Relapse in Inflammatory Bowel Disease: A Meta-Analysis.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the utility of fecal calprotectin (FC) in predicting relapse and endoscopic activity during follow-up in an inflammatory bowel disease (IBD) cohort.
methodsAll FC measurements that were obtained during a 3-year period from patients with inflammatory bowel disease in clinical remission were identified. Data regarding the short-term (6 mo) course of the disease were extracted from the medical files. Exclusion criteria were defined as: (1) An established flare of the disease at the time of FC measurement, (2) Loss to follow up within 6 mo from baseline FC measurement, and, (3) Insufficient data on file. Statistical analysis was performed to evaluate whether baseline FC measurement could predict the short term clinical relapse and/or the presence of mucosal healing.
resultsWe included 149 [Crohn's disease (CD) = 113, Ulcerative colitis (UC) = 36, male = 77] IBD patients in our study. Within the determined 6-month period post-FC measurement, 47 (31.5%) had a disease flare. Among 76 patients who underwent endoscopy, 39 (51.3%) had mucosal healing. Baseline FC concentrations were significantly higher in those who had clinical relapse compared to those who remained in remission during follow up (481.0 μg/g, 286.0-600.0
conclusionSerial FC measurements may be useful in monitoring IBD patients in remission, as FC appears to be a reliable predictor of short-term relapse and endoscopic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.